Wedbush Lowers Earnings Estimates for Dianthus Therapeutics

Key Points

• Wedbush has lowered earnings estimates for Dianthus Therapeutics, predicting a Q3 2025 EPS of ($0.83), down from ($0.81), while maintaining an "Outperform" rating with a price target of $42.00.
• The company reported a Q2 loss of ($0.88) EPS, missing analyst expectations, and had a significantly negative net margin of 2,364.56% with revenues falling short of projections.
• Despite the negative earnings outlook, Dianthus Therapeutics' stock has a consensus rating of "Buy" from analysts, with a notable average target price of $54.00.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Wedbush decreased their Q3 2025 EPS estimates for Dianthus Therapeutics in a research note issued on Thursday, August 21st. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.83) for the quarter, down from their previous estimate of ($0.81). Wedbush currently has a "Outperform" rating and a $42.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics' Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($3.40) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million.

Other research analysts have also issued research reports about the stock. William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating on the stock. Robert W. Baird reduced their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH traded up $0.92 during trading hours on Monday, hitting $24.33. The stock had a trading volume of 304,783 shares, compared to its average volume of 360,919. The stock's fifty day simple moving average is $20.19 and its 200 day simple moving average is $20.02. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $32.27. The firm has a market capitalization of $783.18 million, a price-to-earnings ratio of -7.49 and a beta of 1.43.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC lifted its stake in shares of Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock valued at $1,972,000 after purchasing an additional 55,682 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at $1,349,000. Northern Trust Corp lifted its stake in shares of Dianthus Therapeutics by 21.2% in the 4th quarter. Northern Trust Corp now owns 245,523 shares of the company's stock valued at $5,352,000 after purchasing an additional 42,923 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after purchasing an additional 680,000 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after purchasing an additional 3,758 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.